Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TRICOM vector based cancer vaccines.

Charlie T Garnett1, John W Greiner, Kwong-Yok Tsang

  • 1Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute/NIH, Bldg. 10, Rm. 8B09, 10 Center Drive, Bethesda, MD 20892, USA.

Current Pharmaceutical Design
|February 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.

JTO clinical and research reports·2026
Same author

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

Journal for immunotherapy of cancer·2026
Same author

Study protocol: targeted delivery of interleukin-12 in combination with hepatic artery infusion pump therapy for patients with adrenocortical carcinoma liver metastases.

BMC cancer·2026
Same author

Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models.

Frontiers in immunology·2026
Same author

Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma.

Cancer immunology, immunotherapy : CII·2026
Same author

GPR15-guided CD8<sup>+</sup> T regulatory cells control intestinal inflammation.

Nature·2026

Cancer vaccines using poxviruses deliver tumor antigens and a triad of costimulatory molecules (TRICOM) to effectively activate T-cells for tumor eradication. This immunotherapy approach enhances T-cell responses against cancer.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Effective antitumor T-cell responses require T-cells specific for tumor antigens.
  • Tumor antigens often lack immunogenicity, and solid tumors lack costimulatory molecules, hindering T-cell activation.
  • Active immunotherapy aims to overcome this unresponsiveness by generating immune responses against tumor-associated antigens (TAAs).

Purpose of the Study:

  • To review preclinical findings and clinical applications of TRICOM-based vaccines for cancer immunotherapy.
  • To highlight the use of poxviruses as delivery vehicles for TAAs combined with T-cell costimulatory molecules.

Main Methods:

  • Utilizing poxviruses as delivery vectors for TAAs and T-cell costimulatory molecules.
  • Engineering viral vectors to express a TRIad of COstimulatory Molecules (TRICOM: B7-1, ICAM-1, LFA-3) alongside TAA transgenes.

Related Experiment Videos

Main Results:

  • Insertion of costimulatory molecule transgenes into viral vectors significantly enhances immune responses to TAAs.
  • TRICOM demonstrated superior enhancement of T-cell responses to TAAs compared to single or dual costimulatory molecules.
  • Preclinical data and clinical applications of TRICOM-based vaccines show promising results in cancer immunotherapy.

Conclusions:

  • TRICOM-based vaccines represent a potent strategy for cancer immunotherapy by enhancing T-cell activation against tumors.
  • Poxvirus vectors effectively deliver TAAs and costimulatory molecules, leading to robust antitumor immune responses.
  • TRICOM-based cancer vaccines hold significant potential for clinical application in treating various cancers.